<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627393</url>
  </required_header>
  <id_info>
    <org_study_id>557</org_study_id>
    <secondary_id>U01HL072268</secondary_id>
    <secondary_id>HL072268</secondary_id>
    <secondary_id>HL072291</secondary_id>
    <secondary_id>HL072196</secondary_id>
    <secondary_id>HL072248</secondary_id>
    <secondary_id>HL072191</secondary_id>
    <secondary_id>HL072305</secondary_id>
    <secondary_id>HL072028</secondary_id>
    <secondary_id>HL072072</secondary_id>
    <secondary_id>HL072355</secondary_id>
    <secondary_id>HL072283</secondary_id>
    <secondary_id>HL072346</secondary_id>
    <secondary_id>HL072331</secondary_id>
    <secondary_id>HL072290</secondary_id>
    <nct_id>NCT00627393</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)</brief_title>
  <acronym>RING</acronym>
  <official_title>High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia: The RING Study (Resolving Infection in Neutropenia With Granulocytes)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neutropenia, a condition characterized by an abnormally low number of infection-fighting
      white blood cells called neutrophils, commonly develops in people who have undergone
      chemotherapy or hematopoietic stem cell (HSC) transplantation. The severely reduced immunity
      of those with neutropenia can put them at risk of entry of life-threatening infections,
      making the implementation of treatments that increase white blood cell numbers important.
      Several studies have shown that the transfusion of donor granulocytes, a type of white blood
      cell that includes neutrophils, is effective in promoting the recovery of adequate numbers of
      granulocytes. However, granulocyte transfusions can cause side effects, and it is not known
      whether the success of the therapy outweighs the health risks of the side effects. This study
      will evaluate the safety and effectiveness of granulocyte transfusions in treating people
      with a bacterial or fungal infection during neutropenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thousands of people each year are hospitalized for neutropenia, which continues to cause
      substantial morbidity and mortality for those affected. Neutropenia is primarily caused by
      chemotherapy and various other cancer treatments, such as radiation therapy, biotherapy, and
      HSC transplantation. Signs and symptoms of neutropenia may include high fever, chills, sore
      throat, and diarrhea. In neutropenia, the number of neutrophils, a type of granulocyte, is
      greatly reduced, weakening the body's immune system and increasing the risk of infection.
      Therefore, a method to provide adequate numbers of functional granulocytes to people with
      neutropenia could be of greatest benefit for recovery. Administration of a combination of two
      drugs, granulocyte colony-stimulating factor (G-CSF) and dexamethasone, has been show to
      stimulate the body to produce a large number of granulocytes. Granulocyte transfusions
      obtained from donors who have received these two drugs may help people with low white blood
      cell counts fight infections until their own white blood cell counts recover. However, it is
      not clear whether the benefits of granulocyte transfusions outweigh the risks of side
      effects. This study will compare the safety and effectiveness of granulocyte transfusions
      with standard antimicrobial therapy versus the safety and effectiveness of standard
      antimicrobial therapy alone in increasing granulocyte numbers and in improving survival rates
      in people with bacterial or fungal infection during neutropenia.

      Participation in the research portion of this study will last about 3 months. All
      participants who were not previously receiving treatment with standard antimicrobial therapy
      will begin therapy immediately upon study entry. Participants will then be assigned randomly
      to receive either granulocyte transfusion plus continued antimicrobial therapy or continued
      antimicrobial therapy alone. All participants will be monitored for a maximum of 42 days,
      during which they will provide information on medical history and ongoing status of
      antimicrobial therapy. Daily blood samples to measure white blood cell count will be obtained
      from participants until samples show that participants are making their own granulocytes.
      Samples will then be collected weekly until Day 42. There may be additional blood draws
      depending on the type of infection present in participants.

      Granulocyte transfusions will be given daily during the 42-day treatment period, depending on
      granulocyte donor availability. Blood counts will be checked immediately before and after
      each transfusion to measure granulocyte levels. Transfusions will be stopped if participants
      start making their own granulocytes, experience serious side effects, or show a reduction in
      infection. At Month 3 after study entry, follow-up information will be collected about all
      participants' health status through reviewing their medical records and contacting their
      physicians.

      Participation for granulocyte donors will last 1 week from the time of donation. Community
      donors may provide more than one granulocyte donation, but no more than one donation every 3
      days. Frequency of donation from a family member will be according to local blood bank
      criteria with approval from a blood bank physician. Both community donors and family donors
      are limited to eight donations each year. Twelve hours before each donation, participants
      will be injected with Neupogen, which contains G-CSF, and they will take one dose of
      dexamethasone by mouth. Participants will then undergo a blood draw, followed by a procedure
      using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours
      and will involve the drawing of blood from each arm, the separation of granulocytes from the
      red blood cells and plasma in the machine, and the return of the red blood cells and plasma
      to the participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response</measure>
    <time_frame>Measured at Day 42</time_frame>
    <description>Microbial response was defined as follows:
A negative blood culture test at 42 days after randomization for subjects with fungemia (candidemia or fusariosis) or bacteremia.
Improvement of signs and symptoms of infectious disease (complete or partial response) at 42 days after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alloimmunization, Defined as the Appearance of Anti-human Leukocyte Antigen (HLA) or Antineutrophil Antibodies</measure>
    <time_frame>Measured at Days 14 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Granulocyte Transfusion Reactions, Including Febrile, Allergic, and Pulmonary Reactions (Transfusion Arm Only)</measure>
    <time_frame>Measured within 6 hours after end of transfusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Versus Host Disease Among Recipients of Allogeneic Stem Cell Transplantation</measure>
    <time_frame>Measured at Day 42</time_frame>
    <description>Time to GVHD incidence between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Incidence of Adverse Effects</measure>
    <time_frame>Measured through Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Resolution</measure>
    <time_frame>Measured through Day 42</time_frame>
    <description>Fever resolution between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Negative Test for Fungal Antigenemia (e.g., Galactomannan Antigenemia Among Participants With Invasive Aspergillosis)</measure>
    <time_frame>Measured at Days 7, 14, and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Negative Blood Culture for Participants With Positive Blood Culture at Baseline</measure>
    <time_frame>Measured through Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Survival</measure>
    <time_frame>Measured at Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events in Granulocyte Donors</measure>
    <time_frame>Measured at Week 1 after G-CSF administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Availability (Proportion of Scheduled Granulocyte Transfusion Days on Which Granulocytes Were Available)</measure>
    <time_frame>Measured through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Granulocyte Yield</measure>
    <time_frame>Measured immediately after each granulocyte donation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of Granulocyte Transfusions Due to Toxicity or Intolerance</measure>
    <time_frame>Measured through Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Neutropenia</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive granulocyte transfusions in addition to standard antimicrobial therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive standard antimicrobial therapy alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard antimicrobial therapy</intervention_name>
    <description>Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Granulocyte transfusions</intervention_name>
    <description>Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10^10 per collection (or proportionately less for participants less than 30 kg in weight).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF/dexamethasone</intervention_name>
    <description>Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Apheresis machine</intervention_name>
    <description>Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe neutropenia (Absolute Neutrophil Count &lt; 500/mm^3) due to marrow failure caused
             by underlying disease or therapy

          -  Must have one of the following: fungemia; bacteremia; proven or presumptive invasive
             tissue bacterial infection; or proven, probable, or presumptive invasive fungal
             infection

        Exclusion Criteria:

          -  Unlikely to survive 5 days

          -  Evidence that patient will not be neutropenic at least 5 days

          -  Previously enrolled in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan F. Assmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Research Institutes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan McFarland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Froedtert Memorial Lutheran Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eliot Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ellis Neufeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston/Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Bussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College, Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cassandra Josephson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Ness, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherrill Slichter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Price, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bloodworks (Puget Sound Blood Center)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Strauss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey McCullough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Sachais, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darrell Triulzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Presbyterian and Shadyside/Children's Hospital Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College, Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chlidren's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Presbyterian and Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin at Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Memorial Lutheran Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2008</study_first_posted>
  <results_first_submitted>December 2, 2014</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2014</results_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulocyte Transfusions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Arm</title>
          <description>Received antimicrobial therapy alone.</description>
        </group>
        <group group_id="P2">
          <title>Granulocyte Arm</title>
          <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intention-To-Treat Analysis</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adjudication indeterminate</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by patient/family/physician</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Per-Protocol Analysis</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Received unstimulated/no granulocytes</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by patient/family/physician</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Control Arm</title>
          <description>Received antimicrobial therapy alone.</description>
        </group>
        <group group_id="B2">
          <title>Granulocyte Arm</title>
          <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="19.8"/>
                    <measurement group_id="B2" value="54.8" spread="16.3"/>
                    <measurement group_id="B3" value="51.9" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.0" spread="23.8"/>
                    <measurement group_id="B2" value="78.7" spread="20.6"/>
                    <measurement group_id="B3" value="77.3" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of neutropenia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chemotherapy only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HST (or preparation for HST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ANC prior to randomization</title>
          <description>ANC = Absolute neutrophil count.
Subjects with ANC less than 500/mm^3 were considered to have severe neutropenia.</description>
          <units>x10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.046" spread="0.091"/>
                    <measurement group_id="B2" value="0.058" spread="0.096"/>
                    <measurement group_id="B3" value="0.052" spread="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Zubrod score</title>
          <description>The Zubrod scoring system ranks patients on their functionality on a scale from 0-5. Zubrod score category &quot;0 to 2&quot; represents asymptomatic, symptomatic but completely ambulatory, or symptomatic and 50% in bed during the day. Zubrod score category &quot;3 to 5&quot; represents symptomatic and more than 50% in bed (but not bedbound), being bedbound or completely disabled, or being moribund.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 to 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 to 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Infection type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bacteremia only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tissue bacterial infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fungemia only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tissue fungal infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response</title>
        <description>Microbial response was defined as follows:
A negative blood culture test at 42 days after randomization for subjects with fungemia (candidemia or fusariosis) or bacteremia.
Improvement of signs and symptoms of infectious disease (complete or partial response) at 42 days after randomization.</description>
        <time_frame>Measured at Day 42</time_frame>
        <population>All adjudicated or deceased subjects in intention-to-treat analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Received antimicrobial therapy alone.</description>
          </group>
          <group group_id="O2">
            <title>Granulocyte Arm</title>
            <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response</title>
          <description>Microbial response was defined as follows:
A negative blood culture test at 42 days after randomization for subjects with fungemia (candidemia or fusariosis) or bacteremia.
Improvement of signs and symptoms of infectious disease (complete or partial response) at 42 days after randomization.</description>
          <population>All adjudicated or deceased subjects in intention-to-treat analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Ordinary multiple logistic regression including treatment arm, infection strata, underlying disease, zubrod score, respiratory symptoms, and age.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>3.20</ci_upper_limit>
            <estimate_desc>Control group is the reference group. Model adjusted for infection strata, underlying disease, zubrod score, respiratory symptoms, and age.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alloimmunization, Defined as the Appearance of Anti-human Leukocyte Antigen (HLA) or Antineutrophil Antibodies</title>
        <time_frame>Measured at Days 14 and 42</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Granulocyte Transfusion Reactions, Including Febrile, Allergic, and Pulmonary Reactions (Transfusion Arm Only)</title>
        <time_frame>Measured within 6 hours after end of transfusion</time_frame>
        <population>Subjects who received granulocyte transfusions. Six subjects in the control group received granulocyte transfusions in violation of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Received antimicrobial therapy alone.</description>
          </group>
          <group group_id="O2">
            <title>Granulocyte Arm</title>
            <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Granulocyte Transfusion Reactions, Including Febrile, Allergic, and Pulmonary Reactions (Transfusion Arm Only)</title>
          <population>Subjects who received granulocyte transfusions. Six subjects in the control group received granulocyte transfusions in violation of the protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No events reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Versus Host Disease Among Recipients of Allogeneic Stem Cell Transplantation</title>
        <description>Time to GVHD incidence between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.</description>
        <time_frame>Measured at Day 42</time_frame>
        <population>Subjects who had allogeneic stem cell transplantation</population>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Received antimicrobial therapy alone.</description>
          </group>
          <group group_id="O2">
            <title>Granulocyte Arm</title>
            <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Versus Host Disease Among Recipients of Allogeneic Stem Cell Transplantation</title>
          <description>Time to GVHD incidence between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.</description>
          <population>Subjects who had allogeneic stem cell transplantation</population>
          <units>proportion of subjects, GVHD incidnence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67"/>
                    <measurement group_id="O2" value="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <p_value_desc>Competing risks analysis for time to GVHD for subjects with allogeneic HST. The sample size was very small (n=7 in the granulocyte group, and n=8 in the control group).</p_value_desc>
            <method>Competing Risks</method>
            <param_type>Log Rank P-Value</param_type>
            <param_value>0.43</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Incidence of Adverse Effects</title>
        <time_frame>Measured through Day 42</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Received antimicrobial therapy alone.</description>
          </group>
          <group group_id="O2">
            <title>Granulocyte Arm</title>
            <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Incidence of Adverse Effects</title>
          <population>All randomized subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Resolution</title>
        <description>Fever resolution between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.</description>
        <time_frame>Measured through Day 42</time_frame>
        <population>Subjects who had fever at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Received antimicrobial therapy alone.</description>
          </group>
          <group group_id="O2">
            <title>Granulocyte Arm</title>
            <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Fever Resolution</title>
          <description>Fever resolution between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.</description>
          <population>Subjects who had fever at baseline.</population>
          <units>proportion of subjects, resolved fever</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89"/>
                    <measurement group_id="O2" value="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Negative Test for Fungal Antigenemia (e.g., Galactomannan Antigenemia Among Participants With Invasive Aspergillosis)</title>
        <time_frame>Measured at Days 7, 14, and 42</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Negative Blood Culture for Participants With Positive Blood Culture at Baseline</title>
        <time_frame>Measured through Day 42</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Survival</title>
        <time_frame>Measured at Month 3</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Received antimicrobial therapy alone.</description>
          </group>
          <group group_id="O2">
            <title>Granulocyte Arm</title>
            <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Survival</title>
          <population>All randomized subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank test to compare survival distributions between the control group and treatment group.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.293</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25885</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.778</ci_lower_limit>
            <ci_upper_limit>2.147</ci_upper_limit>
            <estimate_desc>The control group is considered the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events in Granulocyte Donors</title>
        <time_frame>Measured at Week 1 after G-CSF administration</time_frame>
        <population>237 subjects consented to G-CSF and dexamethasone administration prior to granulocyte donation.</population>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Donors</title>
            <description>Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone
G-CSF/dexamethasone: Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
Apheresis machine: Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events in Granulocyte Donors</title>
          <population>237 subjects consented to G-CSF and dexamethasone administration prior to granulocyte donation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myalgia and backpain of unexpected duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal nucleated red blood cell differential</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Availability (Proportion of Scheduled Granulocyte Transfusion Days on Which Granulocytes Were Available)</title>
        <time_frame>Measured through study completion</time_frame>
        <population>The unit of analysis is patient-days where a granulocyte transfusion was scheduled.</population>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Arm</title>
            <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Availability (Proportion of Scheduled Granulocyte Transfusion Days on Which Granulocytes Were Available)</title>
          <population>The unit of analysis is patient-days where a granulocyte transfusion was scheduled.</population>
          <units>percentage of available granulocyte days</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Granulocyte Yield</title>
        <time_frame>Measured immediately after each granulocyte donation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Donors</title>
            <description>Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone
G-CSF/dexamethasone: Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
Apheresis machine: Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Granulocyte Yield</title>
          <units>Granulocyte Yield (billion cells/liter)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Granulocyte Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.75" lower_limit="89.76" upper_limit="242.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuation of Granulocyte Transfusions Due to Toxicity or Intolerance</title>
        <time_frame>Measured through Day 42</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were reported up to 42 days after randomization.</time_frame>
      <desc>Serious adverse events and other adverse events (i.e. granulocyte transfusion related events) data were collected. The number of participants at risk for other adverse events corresponds to the number of participants who received granulocyte transfusions (6 control arm subjects and 51 granulocyte arm subjects).</desc>
      <group_list>
        <group group_id="E1">
          <title>Control Arm</title>
          <description>Received antimicrobial therapy alone.</description>
        </group>
        <group group_id="E2">
          <title>Granulocyte Arm</title>
          <description>Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time shortened</sub_title>
                <description>PTT (Grade 2)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Increased blast cell count</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Increased blood creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hydraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypokalaemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Increased prothrombin level</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal symptom</sub_title>
                <description>Nausea, vomiting and abdominal pain.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infection in an immunocompromised host</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acute lung injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="36" subjects_affected="17" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="81" subjects_affected="28" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/ hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rigors and Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="42" subjects_affected="15" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="16" subjects_affected="8" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All publications and presentations resulting from studies from the TMH Network must be approved by the Publications and Presentations Committee before submission. The Sponsor (NERI) and funding agency (NHLBI) both are represented on the P&amp;P Committee along with Network Investigators. Members of the P&amp;P Committee can recommend changes to publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Assmann, PhD</name_or_title>
      <organization>New England Research Institutes, Inc.</organization>
      <phone>617-972-3048</phone>
      <email>sassmann@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

